Research and development daily Roche CD20× CD3 dual anti-first-line treatment DLBCL full remission rate of 79%

2020.12.9 Research and Development NEWS: Oncopeptides Publishes New Data for Multiple Myeloma II. Phase ANCHOR Joint Study; Pfizer Releases CD3 Dual Anti-Treatment Multiple Myeloma Phase I Data; Cochrane Bio23 Price Pneumonia Vaccine Approved in China; Amgen KRAS Inhibitor Identified by FDA Breakthrough Therapy; Alzheimer's New Target Path - Drp1-HK1-NRP3... We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference.
(click on the title, read the original article) "Drug Development" to reduce bleeding rate 83% Haemophilia B gene therapy the first Phase 3 clinical trial reached the main endpoint uniQure in ASH 2020 announced the treatment of haemophilia B in the study of gene therapy etranacogene dezaparvovec key Phase 3 clinical trial latest data.
results showed that after 26 weeks of treatment, the level of coagulation factor IX activity in patients increased from less than 2% of the baseline to 37.2%, reaching the first major endpoint of the study.
Oncopeptides published new data from the Multiple Myeloma II. Phase ANCHOR Joint Study Oncopeptides AB recently released positive data on the efficacy and safety of the ongoing Phase II ANCHOR Joint Study at ASH 2020: the total remission rate of melofinga symison joint Darato monoanti was 73% and the total mitigation rate of combined boronitzomi was 62%.
used jointly with Dalato monoantigen, the median non-progressed lifetime was 12.9 months.
Roche CD20× CD3 dual-anti-first-line treatment DBCL full remission rate 79% Roche at the ASH2020 Conference announced 3 in the study of dual-specific antibody drug mosunetuzumab (CD2) The latest clinical data from 0×CD3), glofitamab (CD20×CD3), and cevostamab (FCRH5×CD3) show positive results for many types of blood tumors.
eastward pharmaceutical company announced the results of the ADC drug TAA013 I study on December 9, Dongdong Pharmaceuticals announced that its self-developed antibody association drug TAA013 Phase I clinical results were released at the 2020 San Antonio Breast Cancer Conference (SABCS) and presented in the form of an electronic wall report.
Lingteng Pharma completed the first patient of phase III clinical treatment of Catoso gastric cancer worldwide 9, Lingteng Pharma announced that Catumaxomab double resistance on October 6 completed the first patient in Taiwan in the first phase of the global phase III clinical study of gastric cancer, and recently conducted clinical trials in South Korea subjects into the group.
ASH2020 | Pfizer announced CD3 dual-anti-treatment multiple myeloma Phase I data 7, Pfizer announced its targeted B-cell mature antigen (BCMA)-CD3 dual-specific antibody PF-06863135 treatment recurrence/refractic multiple myeloma Phase I clinical study safety and effectiveness data.
data from 30 patients with relapsed/refractive MM showed that all doses of subsuplisive injections were safe and controllable, and dose-limiting toxic reactions were not observed.
A year later, FVIII activity levels Pfizer Haemophilia A gene therapy updated Phase 1/2 results were followed for at least one year in five patients in the high-dose queue for the gene therapy, all of which maintained consistent levels of human coagulation factor VIII (FVIII) activity.
color analysis showed that from week 9 to week 52, the median FVIII activity in the treatment group was 56.9% and the geometric average FVIII activity was 70.4%.
Bollinger Ingehandabyga group ester prevention and treatment of children aged 0-18 years old VTE by CHMP positive evaluation recently, Bollinger Ingham announced that the European Medicines Agency CHMP has adopted the submitted for the treatment of venous thrombosis in children under 18 years of age and prevention of VTE recurrence adaptation.
studies have shown that dabiga esters have good safety outcomes for children with VTE and risk factors for persistent thrombosis.
Drug Approval: Coxing Bio23 Price Pneumonia Vaccine was approved for listing in China on the 9th, Koxing Holding Biotechnology Co., Ltd. announced that its subsidiary Koxing Bio developed a 23-price pneumococcal polysaccharide vaccine has been issued by NMPA on December 2nd, "Drug Registration Approval", will soon be listed.
Repotrectinib has been awarded a breakthrough therapy title for the treatment of ROS1-positive metastasis NSCLC8, Turning Point Therapeutics Inc. announced to the outside world that its candidate drug for the treatment of ROS1 tyrosine kinase inhibitors (TKI-naïve) has been awarded the U.S. Food and Drug Administration (FDA) breakthrough therapy.
Kozi bioCT053 all-human anti-BCMA CAR T cell injection into the breakthrough treatment varieties 8, Kozi bio announced that its CT053 all-human anti-BCMA in vitro CAR T-cell injection through the CDE publicity period, into the breakthrough treatment drug varieties, the formulation of adaptation for recurring recurring refractic multiple myeloma (R/R MM).
amgen KRAS inhibitor by the FDA breakthrough therapy to submit a new drug application by the end of the year, Amgen announced that the U.S. FDA has awarded it in the study of KRASG12C inhibitor sotorasib breakthrough therapy identified for the treatment of local late stage or metastasis carrying KRASG12C mutation of non-small cell lung cancer patients.
the same time, Amjin announced that Sotorasib had been included in the FDA's real-time oncology review pilot program, which is expected to further accelerate its review.
more than 3 billion PPI inhibitor "Esomeprazole sodium" to add troublers! On the evening of the 8th, Chongqing Lemie Pharmaceuticals issued a corporate announcement, its company recently received the State Drug Administration approved the issuance of injection of sodium Esomeprazole "drug registration certificate", approved for listing.
Johnson ampere Amivantamab dual anti-domestic start-up Phase III clinical has submitted BLA8 to the FDA, Johnson and Johnson for the first time in China launched EGFR/c-Met dual anti-Amivantamab Phase III clinical, combined with the third generation EGFR inhibitor Lazertinib first-line treatment of late-stage non-removable NSCLC.
that the double resistance is a "breakthrough therapy" Sino-American dual-certified products, Johnson and Johnson has recently submitted to the FDA biological products licensing application.
the first in China! Hengrui "deoxynephrine ketogenic acid solution" reported on the 7th, CDE official website shows that Hengrui submitted a class 3 generic drug "deoxynephrine ketone acid solution" listing application, for cataract surgery or artificial crystal replacement surgery to maintain the size of the pupil, to prevent the pupil in the operation to shrink and relieve pain in the eyes after surgery.
Hengrui dry eye disease new drug NOV03 (perfluorohexyl octane) was approved for clinical 7, Hengrui Pharmaceuticals issued a notice that recently received the Approval Notice of Drug Clinical Trials approved by the State Drug Administration.
NMPA approved SHR8058 eye drops to treat dry eye disease associated with blephard gland dysfunction.
, the product has invested a cumulative total of about 28.16 million yuan in research and development.
(Xinhua) -- The Lancet, a non-severe patient in the vaccine group, published detailed results of the AZ/Oxford New Coronary Vaccine today, and AstraZenecom announced that the results of a mid-term analysis of a Phase 3 clinical project conducted by Oxford University on the candidate new corona vaccine AZD1222 have been peer-reviewed and published in The Lancet.
the results showed that the vaccine was safe and effective in preventing COVID-19 from developing symptoms and could prevent serious illness and hospitalization.
the effect of metformin on lung cancer survival? A study by IARC involved in a large-scale study to accumulate new evidence from IARC found that metformin was associated with improved survival rates in all lung cancer patients, especially in patients with local (TNM stage II-III) lung squamous cancer.
findings were published recently in the British Journal of Cancer. data from nearly 30,000 people in the
JAMA sub-journal suggest that preventing bone pine fractures For how long bisphosphonates lasted compared to women who had only been treated for 5 years, those who took oral bisphosphonates for more than 7 or 10 years did not reduce the overall risk of hip fractures over the next five years (6-10 years).
team noted that the potential benefits of two years of continued medication, rather than five years, for the prevention of hip fractures should be looked at, as well as whether the potential benefits varied for women at different risk of fractures.
The mechanisms that lead to AD-related cell damage and cognitive impairment remain unclear, despite decades of progression in understanding the pathogenesis of Alzheimer's disease, Drp1-HK1-NLRP3, a new target path path for Alzheimer's disease.
recently, researchers at Case Western Reserve University School of Medicine discovered a new target path path for AD progression, Drp1-HK1-NLRP3, which will help develop treatments for early intervention in neurodegenerative diseases.